Description
Teprotumumab, sold under the brand name Tepezza, is a medication used to treat adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards
It is a human monoclonal antibody developed by Genmab and Roche. It binds to IGF-1R. Teprotumumab was approved for use in the United States in January 2020.